C. Leopold

发表

The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative—Experiences from engaging with pharmaceutical policy makers

S. Vogler, N. Zimmermann, C. Leopold, 2014 .

Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.

H. Leufkens, S. Vogler, K. de Joncheere, 2013, Health policy.

Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer

Christine Y. Lu, C. Earle, D. Ross-Degnan, 2016, Breast Cancer Research and Treatment.

The Impact of the Affordable Care Act on Cancer Survivorship.

E. Park, L. Nekhlyudov, C. Leopold, 2017, Cancer journal.

The Complex Cancer Care Coverage Environment — What is the Role of Legislation? A Case Study from Massachusetts

Christine Y. Lu, A. Wagner, C. Leopold, 2020, Journal of Law, Medicine & Ethics.

Defining Value of Cancer Therapeutics-A Health System Perspective.

J. Peppercorn, A. Wagner, S. Y. Zafar, 2018, Journal of the National Cancer Institute.

A rapidly changing global medicines environment: How adaptable are funding decision-making systems?

S. Morgan, A. Wagner, C. Leopold, 2017, Health policy.

Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program

M. Gilkey, A. Wagner, C. Leopold, 2019, PharmacoEconomics - Open.

Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand

Christine Y. Lu, A. Wagner, C. Leopold, 2020, BMC Health Services Research.

Access to medicines through health systems in low- and middle-income countries

S. Ozawa, Samuel Orubu, R. Shankar, 2019, Health policy and planning.

An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries.

S. Morgan, P. Bach, C. Good, 2018, Health policy.

Thirty Years of Media Coverage on High Drug Prices in the United States--A Never-Ending Story or a Time for Change?

J. Chambers, A. Wagner, C. Leopold, 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage

S. Morgan, A. Wagner, C. Leopold, 2017, Canadian Medical Association Journal.

Pharmaceutical policies in European countries in response to the global financial crisis

S. Vogler, N. Zimmermann, K. de Joncheere, 2011, Southern med review.

Expanding Coverage of Oncology Drugs in an Aging, Upper-Middle-Income Country: Analyses of Public and Private Expenditures in Chile

Jonathan J. Darrow, Veronica Vargas, Marianela Castillo-Riquelme, 2019, Journal of global oncology.

EMINET. Generics in small markets or for low volume medicines

J. Rovira, C. Leopold, C. Habl, 2010 .

Pharmaceutical policy analysis – A European perspective on pricing and reimbursement in challenging times

C. Leopold, 2014 .

Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans

Christine Y. Lu, C. Earle, D. Ross-Degnan, 2018, Breast Cancer Research and Treatment.

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries

Sabine Vogler, Anita K Wagner, Dennis Ross-Degnan, 2014, Bulletin of the World Health Organization.

Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab.

A. Mantel‐Teeuwisse, J. Espín, S. Vogler, 2013, Health policy.

Send Orders of Reprints at Reprints@benthamscience.net Discounts and Rebates Granted for Medicines for Hospital Use in Five European Countries

S. Vogler, N. Zimmermann, C. Leopold, 2022 .

Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna

S. Vogler, C. Leopold, C. Habl, 2014, Journal of pharmaceutical policy and practice.

Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses

D. Ross-Degnan, A. Mantel‐Teeuwisse, S. Vogler, 2014, International Journal for Equity in Health.

Surveying, Assessing and Analysing the Pharmaceutical Sector in the 25 EU Member States

Katja Antony, B. Fröschl, D. Arts, 2006 .

Differences in external price referencing in Europe: a descriptive overview.

H. Leufkens, S. Vogler, K. de Joncheere, 2012, Health policy.

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries

H. Leufkens, S. Vogler, K. de Joncheere, 2012, Southern med review.